Results 91 to 100 of about 6,579 (240)

Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis [PDF]

, 2016
There is significant heterogeneity in the clini- copathological characteristics of intermediate hepatocellu- lar carcinoma (IHCC). This also translates to treatment as transarterial chemoembolization (TACE) is used as first- line therapy for patients ...
David J. Pinato, Elias Allara, Jeong Won Jang, Keiichi Kubota, Mario Pirisi, Masatoshi Kudo, Mitsuru Ishizuka, Ramya Ramaswami, Rohini Sharma, Tadaaki Arizumi, Young Woon Kim   +10 more
core   +1 more source

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

CA: A Cancer Journal for Clinicians, Volume 75, Issue 6, Page 498-527, November/December 2025.
Abstract Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients
Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky   +12 more
wiley   +1 more source

Hepatopulmonary Shunt Ratio Verification Model for Transarterial Radioembolization

Current Radiopharmaceuticals
Introduction: The most important toxicity of transarterial radioembolization therapy applied in liver malignancies is radiation pneumonitis and fibrosis due to hepatopulmonary shunt of Yttrium-90 (90Y) microspheres. Currently, Technetium-99m macroaggregated albumin (99mTc-MAA) scintigraphic images are used to estimate lung shunt fraction (LSF) before ...
Nami Yeyin, Fahrettin Fatih Kesmezacar, Duygu Tunçman, Özge Demir, Lebriz Uslu-Beşli, Osman Günay, Mustafa Demir   +6 more
openaire   +3 more sources

Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality

Hepatology International, 2016
Hepatocellular carcinoma (HCC) of intermediate stage consists of diverse tumor and patient factors in terms of tumor number, size and liver function resulting in various outcomes given by transarterial chemoembolization (TACE). Transarterial radioembolization (TARE) using radioactive isotope, β-ray emitting Yttrium-90 with a short half-life and ...
Do Young, Kim, Kwang-Hyub, Han
openaire   +3 more sources

In silico assessment of cellular damage from Lu‐177, Ac‐225, and Pb‐212 therapeutic radionuclides

Medical Physics, Volume 52, Issue 11, November 2025.
Abstract Background Targeted radionuclide therapy (TRT) has emerged as a unique and effective treatment modality for cancer. Monte Carlo simulations have greatly advanced investigations into radiation‐caused DNA damage, including the complexity of this damage.
Konstantinos P. Chatzipapas, Konstantinos Papachristou, Dimitris Visvikis, Sebastien Incerti, John D. Hazle, George C. Kagadis   +5 more
wiley   +1 more source

Hepatocellular carcinoma [PDF]

, 2018
Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer.
Gores, Gregory, Llovet i Bayer, Josep Maria, Pikarsky, Eli, Sangro, Bruno, Schwartz, Myron, Sherman, Morris, Zucman-Rossi, Jessica   +6 more
core   +1 more source

Liver‐directed therapies for colorectal liver metastases

Cancer, Volume 131, Issue 20, 15 October 2025.
Abstract Colorectal cancer is the third most common cancer diagnosed in the United States, with an anticipated 53,000 deaths from this disease in 2025. Greater than one in five patients will present with synchronous colorectal liver metastases (CRLMs), and 25%–30% will develop CRLMs during the course of the disease.
Andrew D. Folkerts, Lauren M. Janczewski, Ryan P. Merkow   +2 more
wiley   +1 more source

Management strategies for advanced hepatocellular carcinoma with portal vein tumor thrombosis [PDF]

The Ewha Medical Journal
Hepatocellular carcinoma with portal vein tumor thrombosis presents a significant therapeutic challenge due to its poor prognosis and limited treatment options.
Jeayeon Park, Su Jong Yu
doaj   +1 more source

Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: A systematic review [PDF]

, 2015
Background: Unresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite standard systemic treatments which confer minimal survival benefits and significant adverse effects.
Bester, L, Morris, D, Saxena, A, Shan, J, Shan, L, Yang, L.   +5 more
core   +1 more source

Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis [PDF]

, 2016
PURPOSE Liver metastases from renal cell carcinoma (RCC) are not uncommon in the course of disease. However, data about tumor response to intraarterial therapy (IAT) are scarce.
Chapiro, Julius, Duran, Rafael, Fleckenstein, Florian Nima, Gebauer, Bernhard, Geschwind, Jean-Francois, Lin, MingDe, Marshall, Karen, Sahu, Sonia, Salem, Riad, Schernthaner, Ruediger Egbert, Sohn, Jae Ho   +10 more
core   +1 more source